Kindler syndrome

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

Retrieved on: 
Monday, July 25, 2022
Data monitoring committee, NIH, Epidermolysis bullosa simplex, Skin, GLOBE, Epidermolysis bullosa, INM, DMC, U.S. Securities and Exchange Commission, EB, Research, Ageing, Junctional epidermolysis bullosa (medicine), Person, Health, Patent, Adult, Safety, News, Kindler syndrome, Clinical trial, Review, CBN, Disease, Company, Senior, Gastrointestinal tract, Patient, Adolescence, Nasdaq, Cannabinoid, INMED, Therapy, Annual report, EBS, Cannabinol, Security, Risk, Pharmaceutical industry

The inclusion of adolescents will have a positive impact in the enrollment rate for the remainder of the clinical trial.

Key Points: 
  • The inclusion of adolescents will have a positive impact in the enrollment rate for the remainder of the clinical trial.
  • With the DMC approval to enroll adolescent patients into InMeds INM-755 Phase 2 clinical trial, the first adolescent patient with EB has been enrolled into the clinical trial and has completed treatment at the clinical site in Greece.
  • This patent allows for the use of topically administered CBN in patients with epidermolysis bullosa simplex (EBS).
  • InMeds Phase 2 clinical trial now has eight clinical trial sites fully activated to screen and enroll patients.

InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 10, 2021
Population, GMP, Industry, CBN, Food, Neuroprotection, Insurance, Cannabinoid, Cell death, Acquisition, Pain, Glaucoma, Neurodegeneration, Wound healing, Safety, Intraocular pressure, Good manufacturing practice, Neuromuscular junction, Method, Trial of the century, Research, Clinical trial, Conference, GLOBE, Patient, Retinal ganglion cell, CBC, Cannabinol, EB, Drug discovery, Ethics, CEO, Disease, Inflammation, INM, Good, Patent Cooperation Treaty, Neuron, Ophthalmology, Investment, US Foods, Company, Nasdaq, Kindler syndrome, Skin, INMED, Pharmaceutical industry, Fine chemical, Vaccine, Security (finance)

VANCOUVER, British Columbia., Nov. 10, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced financial results for the first quarter of fiscal year 2022 which ended September 30, 2021.

Key Points: 
  • VANCOUVER, British Columbia., Nov. 10, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced financial results for the first quarter of fiscal year 2022 which ended September 30, 2021.
  • The first quarter of fiscal 2022 saw positive momentum across all of our programs, says Eric A. Adams, InMed President & CEO.
  • InMed will be hosting analyst update teleconferences on a semi-annual basis, with the next teleconference to be hosted for the second quarter 2022 fiscal results.
  • InMed also plans to host a webinar to discuss the integration of BayMedica and outline corporate plans for calendar year 2022.

Medical Marijuana Cannabidiol Pipeline Insight Report 2021: Focus on 25 Companies & 50 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, October 18, 2021
Tobacco, Retail, Alternative Medicine, Health, Olive oil, EB, Diabetes, CB2, Pharma, Endothelium, Obstructive sleep apnea, TS, Agitation, Dermatomyositis, PEA, Cancer, Depression, Cannabinoid, INMED, Pain, Red, Spasticity, Epidermolysis bullosa, Systemic scleroderma, Health, Cystic fibrosis, Medical cannabis, THC, Therapy, Nausea, Multiple sclerosis, Disease, Neuromuscular junction disease, Fibroblast, Inflammation, Patient, Tourette syndrome, Dementia, Appetite, Chronic pain, Cannabinol, Arthritis, Hidradenitis suppurativa, Swelling, Entourage effect, University College London, Mergers and acquisitions, Safety, Dronabinol, Anxiety, Research, Muscle, III, Kindler syndrome, Timeline of cannabis laws in the United States, OSA, UCL, Dietary supplement, Drug, Pharmaceutical industry

"Medical Marijuana - Cannabidiol - Pipeline Insight, 2021" report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape.

Key Points: 
  • "Medical Marijuana - Cannabidiol - Pipeline Insight, 2021" report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape.
  • Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD.
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medical Marijuana - Cannabidiol?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Medical Marijuana - Cannabidiol therapeutics?

InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

Retrieved on: 
Thursday, September 30, 2021
Epidermolysis bullosa, Cannabinol, Inflammation, CBN, Cannabinoid, EB, Wound healing, Patient, Senior, INM, Junctional epidermolysis bullosa (medicine), CEO, Clinical trial, Company, Kindler syndrome, Pain, Lists of diseases, Disease, Safety, Glaucoma, INMED, Nasdaq, Blister, Skin, GLOBE, Pharmaceutical industry

This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease.

Key Points: 
  • This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease.
  • Clinical Trial Applications (CTAs) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel).
  • The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly.
  • The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options, statedAlexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed.

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

Retrieved on: 
Friday, September 24, 2021
Intraocular pressure, Cannabinol, Toronto Stock Exchange, Insurance, Research, TSX, Neuroprotection, MD Anderson Cancer Center, Economics, Cannabinoid, Conference, EB, GLP, Wound healing, Patient, Ophthalmology, MD, INM, Junctional epidermolysis bullosa (medicine), Acquisition, Clinical trial, Company, Kindler syndrome, Safety, Glaucoma, INMED, Investment, Nasdaq, Industry, Corporate development, GLOBE, Animal, Internet service provider, Cryptocurrency, Fine chemical, Pharmaceutical industry, Life insurance

VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.
  • The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks.
  • Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches.
  • At June 30, 2021, the Companys total issued and outstanding shares were 8,050,707.